ADHD medication use has increased, but some still do not receive needed treatment
October 11, 2018
Dr. Til Stürmer has co-authored a study showing that the use of medications to treat attention deficit hyperactivity disorder (ADHD) is on the rise in both adults and children worldwide, though at varying rates. The study, which analyzed the electronic patient records of more than 154 million people from 14 countries, was published in The Lancet Psychiatry.
is a co-author on the paper. The study between 2001 and 2015 and provides
New study finds gene variant predisposes people to Type 2 diabetes and also low body weight
October 2, 2018 A new study finds that a well-known gene variant linked to Type 2 diabetes also may predispose a person to being leaner or having a lower body weight. The findings are striking, as many individuals with Type 2 diabetes are obese. The work is one of the first examinations of the gene in a very large, representative sample of diverse Hispanics and Latinos. Photo courtesy of Rutgers School of Nursing.
Gillings School researchers contribute to special issue of Journal of Interpersonal Violence
September 23, 2018 This fall, the Journal of Interpersonal Violence will publish a special issue, "Preventing violence: The role of public policies in preventing intimate partner violence, teen dating violence, and sexual violence." The issue features several articles by Gillings School researchers, including the commentary, "Leveraging Data to Strengthen Campus Sexual Assault Policies," published online Sept. 5. Photo by Ed Yourdon.
Study demonstrates benefits among people living with HIV who inject drugs
September 5, 2018 Gillings School researchers are part of an international team reporting promising findings related to the prevention of HIV transmission among people who are HIV-positive and use injectable drugs and their partners. The key findings of HPTN 074, part of the HIV Prevention Trials Network (HPTN), were published Aug. 30 in The Lancet.
Stürmer offers principles and considerations for effective academia-industry collaboration in pharmacoepidemiology
September 1, 2018 Dr. Til Stürmer has co-authored a set of guiding principles and considerations that public-private partners can use in pharmacoepidemiological research to create scientifically sound research studies that also acknowledge the different interests of academics and industry.
Study finds behavioral changes insufficient to prevent early childhood obesity
August 16, 2018 Results from the longest and largest obesity prevention intervention ever tested in young children showed that children and their families in low-income communities were able to make some sustainable behavioral changes to their diet and activity level. In the end, however, rates of early childhood obesity were unchanged.
Diabetes drug therapy found to be easier on eyes than previously suspected
August 2, 2018 New research on the impact of incretin-based therapies (IBTs) in older adults with diabetes shows this type of therapy may not increase the risk for diabetic retinopathy, a complication of diabetes that threatens sight.
Researchers conduct most diverse genetic study of female reproductive milestones to date
July 25, 2018 A new study is the first to examine multiple genes that influence the age at which a woman starts her period and experiences menopause among a large sample of United States women of diverse ancestries. The findings highlight the benefits of including diverse populations in studies of the genetics of female growth and development.
Former inmates at high risk for opioid overdose following prison release
July 19, 2018 A recent study in North Carolina found that, in the first two weeks after being released from prison, former inmates were 40 times more likely to die of an opioid overdose than someone in the general population.
Gillings researchers fight emerging diseases
July 5, 2018 Utilizing the expertise of the Baric Lab at the UNC Gillings School, Gilead Sciences is making breakthroughs in developing drugs to fight some of the world’s deadliest viruses. The Gilead broad-spectrum treatment that was tested and proven in the Baric Lab, now known as Remdesivir, was deployed for use in the Ebola outbreak in the Democratic Republic of the Congo.
